News
2024-09-02

Skyline Therapeutics’ Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
2024-05-07

Skyline Therapeutics Presents Multiple New Data at ASGCT 2024
2023-12-12

Skyline Therapeutics Receives China NMPA’s Approval of IND for SKG0201, a Novel SMN1 Gene Replacement Therapy Candidate for Spinal Muscular Atrophy (SMA)
2023-10-19

Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
2023-07-03

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
2023-05-17

Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023
2023-05-03

Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting
2022-12-16

Skyline Therapeutics’ Novel AAV Gene Therapy for Ocular Disease Enters Clinical Trial
2022-01-10

China Eye Valley and Skyline Therapeutics sign memorandum of understanding to jointly advance ocular gene therapy practices
2022-01-01

Skyline announces Chief Development Officer as it advances multiple innovative research programs towards clinical stage
2021-12-17

BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
2021-09-28

Skyline’s GMP manufacturing plant successfully completes large-scale high-quality viral vector production
2020-08-17

Geneception (now Skyline Therapeutics) R&D center launches in Zhangjiang Science City, equipped with cutting-edge gene therapy platforms